A detailed history of Royal Bank Of Canada transactions in Equillium, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 29 shares of EQ stock, worth $39. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29
Previous 29 -0.0%
Holding current value
$39
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.73 - $3.0 $83 - $342
-114 Reduced 79.72%
29 $0
Q4 2023

Feb 14, 2024

SELL
$0.48 - $0.74 $74 - $115
-156 Reduced 52.17%
143 $0
Q3 2023

Nov 14, 2023

SELL
$0.72 - $0.9 $120 - $151
-168 Reduced 35.97%
299 $0
Q2 2023

Aug 14, 2023

BUY
$0.49 - $0.79 $228 - $368
467 New
467 $0
Q3 2022

Nov 14, 2022

BUY
$1.93 - $3.14 $214 - $348
111 New
111 $0
Q3 2021

Nov 15, 2021

SELL
$4.84 - $6.91 $484 - $691
-100 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$5.11 - $7.64 $511 - $764
100 New
100 $1,000

Others Institutions Holding EQ

About Equillium, Inc.


  • Ticker EQ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,352,100
  • Market Cap $47.1M
  • Description
  • Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...
More about EQ
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.